H-ILSLELMKL-OH

Rif. 3D-PP45339

Informazioni sul prodotto

• Nome: H-ILSLELMKL-OH
• Sinonimi: NH2-Ile-Leu-Ser-Leu-Glu-Leu-Met-Lys-Leu-OH

Descrizione

Peptide H-ILSLELMKL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-ILSLELMKL-OH include the following: Generation and evaluation of cancer binding capacity of HLA-A2-WT1 complex-targeting antibody X Yao, S Matosevic - Immunology Letters, 2024 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0165247824000555 Cancer immunotherapy 2006 meets strategies for immune therapy RH Eibl, K Lang, D Palm, B Niggemann - Cancer Immunol , 2007 - researchgate.nethttps://www.researchgate.net/profile/Daniela-Fioretti/publication/215698869_CDR3-targeted_DNA_vaccines_in_B-cell_lymphoma/links/0c9605172c8f9000e4000000/CDR3-targeted-DNA-vaccines-in-B-cell-lymphoma.pdf Myeloid Leukemia Vaccines PM Armistead, JS Serody - Immunotherapy in Translational , 2018 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/9781118684535.ch5 Characterization of T Cell Epitopes of the Receptor for Hyaluronic Acid Mediated Motility (RHAMM/CD168) in Acute Myeloid Leukemia. M Schmitt , L Li, M Ringhoffer, T Barth , M Wiesneth - 2004 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/104/11/2540/54863 Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules M Schmitt , L Li, K Giannopoulos, J Chen - Experimental , 2006 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0301472X06004498 RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses M Schmitt , A Schmitt, MT Rojewski - Blood, The Journal , 2008 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/111/3/1357/25427 RHAMM/CD168-R3 Peptide Vaccination of Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM) Elicits M Schmitt , A Schmitt, K Giannopoulos, L Li, P Liebisch - 2006 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/108/11/409/120275 Indirect induction of regulatory T cells accompanies immune responses during peptide vaccination of chronic lymphocytic leukaemia patients. K Skorka, J Zaleska, M Zajac - British Journal of , 2016 - search.ebscohost.comhttps://search.ebscohost.com/login.aspx?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=00071048&asa=N&AN=116284609&h=AdOX91DsQ%2Fja2nMc0bR35rGlQbMroy518S2M3nXzuedZ52OqldJTjHQwuf7Lsr7f%2B75duOVhvtSIwuZfQcZKBg%3D%3D&crl=c Peptide vaccination induces profound changes in the immune system in patients with B-cell chronic lymphocytic leukemia K Giannopoulos, P Wà ‚asiuk - Folia Histochemica , 2011 - journals.viamedica.plhttps://journals.viamedica.pl/folia_histochemica_cytobiologica/article/view/4158 Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia K Giannopoulos, M Schmitt , M Kowal - Oncology , 2008 - spandidos-publications.comhttps://www.spandidos-publications.com/10.3892/or_00000059 Targets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia K Giannopoulos, M Schmitt - Leukemia & lymphoma, 2006 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/10428190600709721 Peptide vaccination induces dynamic changes in CD4+ and CD8+ T cell subsets: report on the first peptide vaccination trial in patients with chronic K Giannopoulos, M Kowal, A Dmoszynska, J Rolinski - Blood, 2008 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497119504505 Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia K Giannopoulos, L Li - International , 2006 - spandidos-publications.comhttps://www.spandidos-publications.com/ijo/29/1/95 The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell K Giannopoulos, D Mertens , A Buhler, TFE Barth , I Idler - Leukemia, 2009 - nature.comhttps://www.nature.com/articles/leu2008338 Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia K Giannopoulos, A Dmoszynska, M Kowal, J Rolinski - Leukemia, 2010 - nature.comhttps://www.nature.com/articles/leu201029 Motility (RHAMM): Characterization as an Immunotherapeutical Target in Chronic Lymphocytic Leukemia (CLL) and First Results of RHAMM-Derived Peptide K Giannopoulos, A Buhler, J Chen , A Krober, M Kowal - Blood, 2007 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S000649711988299X Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches J Greiner, M Schmitt , L Li, K Giannopoulos, K Bosch - Blood, 2006 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/108/13/4109/6594 Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive J Greiner, L Li, M Ringhoffer, TFE Barth - Blood, 2005 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/106/3/938/21848 RHAMM/CD168-R3 Peptide Vaccination of HLA-A2+ Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM). J Greiner, K Giannopoulos, L Li, P Liebisch, C Wendl - 2005 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/106/11/2781/121765 Imatinib Inhibits Both CD4+ T Regulatory Cells and CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168. J Chen , A Schmitt, B Chen , M Rojewski, J Greiner - 2006 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/108/11/2201/127846 Antigen targets for the development of immunotherapies in leukemia J Bauer, A Nelde , T Bilich , JS Walz - International Journal of Molecular , 2019 - mdpi.comhttps://www.mdpi.com/1422-0067/20/6/1397 Dendritic cells and peptide-based vaccine in multiple myeloma J Bae, RH Prabhala , NC Munshi - Advances in Biology and Therapy of , 2012 - Springerhttps://link.springer.com/chapter/10.1007/978-1-4614-5260-7_6 Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine AE Foster , FV Okur, E Biagi, A Lu, G Dotti, E Yvon - Leukemia, 2010 - nature.comhttps://www.nature.com/articles/leu2009281 The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses A Schmitt, TFE Barth , E Beyer - International , 2009 - spandidos-publications.comhttps://www.spandidos-publications.com/ijo/34/3/629

• Marchio: Biosynth